Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.

Belgique Nouvelles Nouvelles

Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.
Belgique Dernières Nouvelles,Belgique Actualités

Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 6 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 97%

Danaher stock was rising Tuesday after the healthcare company reported third-quarter earnings and revenue that topped Wall Street estimates.

In the same period last year, the company reported earnings of $2.56 a share on revenue of $7.66 billion.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

MarketWatch /  🏆 3. in BE
 

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

FMC Stock Tumbles on Revenue Warning Ahead of EarningsFMC Stock Tumbles on Revenue Warning Ahead of EarningsThe crop protection company cited lower sales in Latin America as a reason for lowering estimates.
Lire la suite »

Agilysys’ stock jumps on revenue, earnings beatAgilysys’ stock jumps on revenue, earnings beatJon Swartz is a senior reporter for MarketWatch in San Francisco, covering many of the biggest players in tech, including Netflix, Facebook and Google. Jon has covered technology for more than 20 years, and previously worked for Barron's and USA Today. Follow him on Twitter jswartz.
Lire la suite »

3M Posts Big Earnings Beat Following Recent Legal Settlements3M Posts Big Earnings Beat Following Recent Legal SettlementsInvestors have reacted to 3M's flurry of announcements by essentially avoiding the stock.
Lire la suite »

Novartis lifts 2023 earnings forecast for third timeNovartis lifts 2023 earnings forecast for third timeSwitzerland's Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for a multiple sclerosis (MS) drug.
Lire la suite »



Render Time: 2025-01-14 08:45:32